 |
The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.
FDA is hosting the Generic Drug User Fee Amendments of 2012; Public Hearing on Policy Development to solicit public comment on certain topics related to implementation of GDUFA and the GDUFA Commitment Letter that accompanies the legislation.
FDA wants your input on the five draft guidance documents FDA has issued or will issue shortly to facilitate implementation of GDUFA. FDA also seeks your input on additional policy priorities under GDUFA, such as the Agency’s consideration of generic drug exclusivity and the category of first generics. We will take the information from the public meeting into account in developing the fiscal year 2015 GDUFA priorities.
The meeting will be held near FDA’s main campus at College Park Marriott Hotel and Conference Center, 3501 University Blvd., East, Hyattsville, MD 20783, MD, on September 17, 2014, from 9:00am-5:00pm
Submit electronic or written requests to make oral presentations by September 3, 2014 and presentation materials are due by September 9, 2014, to GenericDrugPolicy@fda.hhs.gov. Electronic or written comments will be accepted until October 13, 2014. You may submit ideas on GDUFA policy priorities and comments and view the Federal Register notice here.
If you wish to attend, either in person or via webcast, please email GenericDrugPolicy@fda.hhs.gov. We recommend that you register early, because seating is limited. The email should contain complete contact information for each attendee (i.e., name, title, affiliation, address, email address, and telephone number). Those without email access can register by contacting Shaniece Bowens or Connie Wisner at 240-402-7923. If you need special accommodations because of a disability, please be in touch at least seven days before the meeting.
For more information and the latest events regarding GDUFA, please visit our Generic Drug User Fee Amendments of 2012 website. We will post meeting materials as they become available here.
Sign Up for Email Alerts about GDUFA
Federal Register Notice: https://federalregister.gov/a/2014-19632
This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at druginfo@fda.hhs.gov.
- For additional drug information, please visit the DDI Web page.
- For up-to-date drug information, follow the FDA’s Division of Drug Information on Twitter: FDA_Drug_Info.
- This service is provided to you at no charge by the U.S. Food & Drug Administration (FDA).
| This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
